The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non–small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations

BACKGROUND: Lung cancer is a leading cause of cancer morbidity and death in the United States. Non–small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases, and oncogenic mutations in the gene encoding the epidermal growth factor receptor (EGFR) are among its most common genetic causes....

Descripción completa

Detalles Bibliográficos
Autores principales: Hernandez, Luis, Young, Melanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394218/
https://www.ncbi.nlm.nih.gov/pubmed/36373869
http://dx.doi.org/10.18553/jmcp.2022.22251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394218/
https://www.ncbi.nlm.nih.gov/pubmed/36373869
http://dx.doi.org/10.18553/jmcp.2022.22251

Ejemplares similares